Cardiac Failure

Pediatric Cardiovascular Medicine: Second Edition

Volumn , Issue , 2012, Pages 1021-1031

  Kaufman, Beth D ^a   Lin, Kimberly Y ^b   Patel, Akash R ^b   Naim, Maryam Y ^b   Shah, Maully J ^a,b   Shaddy, Robert E ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Cardiomyopathy; Heart failure; Heart transplantation; Ventricular assist devices

Indexed keywords

EID: 84885556958     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444398786.ch71     Document Type: Chapter

References (116)

1. Mann DL, Kent RL, Parsons B, Cooper G. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 1992;85:790-804.
2. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling - concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol 2000;35:569-82.
3. Mann DL. Mechanisms and models in heart failure: a combinatorial approach. Circulation 1999;100:999-1008.
4. Kass DA. Ventricular arterial stiffening: integrating the pathophysiology. Hypertension 2005;46:185-93.
5. Cheung YF. Arterial stiffness in the young: assessment, determinants, and implications. Korean Circ J 2010;40:153-62.
6. Mahony L. Regulation of intracellular calcium con centration in the developing heart. Cardiovasc Res 1996;31(Spec No):E61-7.
7. 2+ exchange activity in patients with end-stage heart failure. Cardiovasc Res 1996;31:48-54.
8. 2+ -exchanger on the force- frequency relation. Basic Res Cardiol 1998;93(Suppl 1):38-45.
9. Cox GF, Sleeper LA, Lowe AM, et al. Factors associated with estab lishing a causal diagnosis for children with cardiomyopathy. Pediatrics 2006;118:1519-31.
10. Goodwin FC, Muntoni F. Cardiac involvement in muscular dystrophies: molecular mechanisms. Muscle Nerve 2005;32:577-88.
11. Scaglia F, Towbin JA, Craigen WJ, et al. Clinical spectrum, morbidity, and mortality in 113 pediatric patients with mitochondrial disease. Pediatrics 2004;114:925-31.
12. Hershberger RE, Lindenfeld J, Mestroni L, et al. Genetic evaluation of cardiomyopathy - a Heart Failure Society of America practice guideline. J Card Fail 2009;15:83-97.
13. Friedrich MG, Sechtem U, Schulz-Menger J, et al. Cardiovascular magnetic resonance in myocarditis: a JACC White Paper. J Am Coll Cardiol 2009;53:1475-87.
14. Cooper LT, Baughman KL, Feldman AM, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. J Am Coll Cardiol 2007;50:1914-31.
15. Towbin JA, Lowe AM, Colan SD, et al. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA 2006;296:1867-76.
16. Daubeney PE, Nugent AW, Chondros P, et al. Clinical features and outcomes of childhood dilated cardiomyopathy: results from a national population-based study. Circulation 2006;114:2671-8.
17. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline update for the diagnosis and management of chronic heart failure in the adult - summary article. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005;46:1116-43.
18. Rosenthal D, Chrisant MR, Edens E, et al. International Society for Heart and Lung Transplantation: practice guidelines for management of heart failure in children. J Heart Lung Transplant 2004;23:1313-33.
19. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987; 316:1429-35.
20. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-10.
21. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991;325:293-302.
22. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 1996;94:2807-16.
23. Packer M, Colucci WS, Sackner-Bernstein JD, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation 1996;94:2793-9.
24. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353:9-13.
25. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353:2001-7.
26. Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. Circulation 2002;106:2194-9.
27. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17.
28. Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003;289:871-8.
29. Kouatli AA, Garcia JA, Zellers TM, et al. Enalapril does not enhance exercise capacity in patients after Fontan procedure. Circulation 1997;96:1507-12.
30. Hechter SJ, Fredriksen PM, Liu P, et al. Angiotensin-converting enzyme inhibitors in adults after the Mustard procedure. Am J Cardiol 2001;87:660-3, A11.
31. Dore A, Houde C, Chan KL, et al. Angiotensin receptor blockade and exercise capacity in adults with systemic right ventricles: a multicenter, randomized, placebo-controlled clinical trial. Circulation 2005;112:2411-6.
32. Shaddy RE, Boucek MM, Hsu DT, et al. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA 2007;298:1171-9.
33. Ezekowitz JA, McAlister FA. Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. Eur Heart J 2009;30:469-77.
34. Kantor PF, Abraham JR, Dipchand AI, et al. The impact of changing medical therapy on transplantation-free survival in pediatric dilated cardiomyopathy. J Am Coll Cardiol 2010;55:1377-84.
35. Canter CE, Shaddy RE, Bernstein D, et al. Indications for heart transplantation in pediatric heart disease: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young; the Councils on Clinical Cardiology, Cardiovascular Nursing, and Cardiovascular Surgery and Anesthesia; and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007;115:658-76.
36. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol 2008;51:e1-62.
37. Narang R, Cleland JG, Erhardt L, et al. Mode of death in chronic heart failure. A request and proposition for more accurate classification. Eur Heart J 1996;17:1390-403.
38. Domanski MJ, Sakseena S, Epstein AE, et al. Relative effectiveness of the implantable cardioverter-defibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias. AVID Investigators. Antiarrhythmics Versus Implantable Defibrillators. J Am Coll Cardiol 1999;34:1090-5.
39. Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS Studies. Antiarrhythmics vs Implantable Defibrillator Study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J 2000;21:2071-8.
40. Moss AJ, Fadl Y, Zareba W, et al. Survival benefit with an implanted defibrillator in relation to mortality risk in chronic coronary heart disease. Am J Cardiol 2001;88:516-20.
41. Bristow MR, Saxon LA, Boehmer J, et al. Cardiacresynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140-50.
42. Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004;350:2151-8.
43. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-37.
44. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 Guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006;114:e385-484.
45. Silka MJ, Bar-Cohen Y. Pacemakers and implantable cardioverter- defibrillators in pediatric patients. Heart Rhythm 2006;3:1360-6.
46. Berul CI. Implantable cardioverter defibrillator criteria for primary and secondary prevention of pediatric sudden cardiac death. Pacing Clin Electrophysiol 2009;32(Suppl 2):S67-70.
47. Silka MJ, Kron J, Dunnigan A, Dick M II. Sudden cardiac death and the use of implantable cardioverter-defibrillators in pediatric patients. The Pediatric Electrophysiology Society. Circulation 1993;87:800-7.
48. Hamilton RM, Dorian P, Gow RM, Williams WG. Five-year experience with implantable defibrillators in children. Am J Cardiol 1996;77:524-6.
49. Groh WJ, Silka MJ, Oliver RP, et al. Use of implantable cardioverter- defibrillators in the congenital long QT syndrome. Am J Cardiol 1996;78:703-6.
50. Stefanelli CB, Bradley DJ, Leroy S, et al. Implantable cardioverter defibrillator therapy for life-threatening arrhythmias in young patients. J Interv Card Electrophysiol 2002;6:235-44.
51. Alexander ME, Cecchin F, Walsh EP, et al. Implications of congenital heart disease and pediatrics. J Cardiovasc Electrophysiol 2004;15:72-6.
52. Goel AK, Berger S, Pelech A, Dhala A. Implantable cardioverter defibrillator therapy in children with long QT syndrome. Pediatr Cardiol 2004;25:370-8.
53. Gradaus R, Wollmann C, Kobe J, et al. Potential benefit from implantable cardioverter-defibrillator therapy in children and young adolescents. Heart 2004;90:328-9.
54. Korte T, Koditz H, Niehaus M, et al. High incidence of appropriate and inappropriate ICD therapies in children and adolescents with implantable cardioverter defibrillator. Pacing Clin Electrophysiol 2004;27:924-32.
55. Werner B, Przybylski A, Kucinska B, et al. Implantable cardioverter- defibrillators in children. Kardiol Pol 2004;60:239-46.
56. Ten Harkel AD, Blom NA, Reimer AG, et al. Implantable cardioverter defibrillator implantation in children in The Netherlands. Eur J Pediatr 2005;164:436-41.
57. Apitz C, Gass M, Dornberger V, et al. The use of implantable cardioverter- defibrillators (ICD) in children and adolescents. Klin Pädiatr 2006;218:270-5 (in German).
58. Eicken A, Kolb C, Lange S, et al. Implantable cardioverter defibrillator (ICD) in children. Int J Cardiol 2006;107:30-5.
59. Berul CI, Van Hare GF, Kertesz NJ, et al. Results of a multicenter retrospective implantable cardioverter-defibrillator registry of pediatric and congenital heart disease patients. J Am Coll Cardiol 2008;51:1685-91.
60. Dubin AM, Berul CI, Bevilacqua LM, et al. The use of implantable cardioverter-defibrillators in pediatric patients awaiting heart transplantation. J Card Fail 2003;9:375-9.
61. Rhee EK, Canter CE, Basile S, et al. Sudden death prior to pediatric heart transplantation: would implantable defibrillators improve outcome?. J Heart Lung Transplant 2007;26:447-52.
62. Shah MJ. Implantable cardioverter defibrillator-related complications in the pediatric population. Pacing Clin Electrophysiol 2009;32(Suppl 2):S71-4.
63. Hsu DT, Pearson GD. Heart failure in children. Part II: diagnosis, treatment, and future directions. Circ Heart Fail 2009;2:490-8.
64. Karpawich PP. Chronic right ventricular pacing and cardiac performance: the pediatric perspective. Pacing Clin Electrophysiol 2004;27:844-9.
65. Thambo JB, Bordachar P, Garrigue S, et al. Detrimental ventricular remodeling in patients with congenital complete heart block and chronic right ventricular apical pacing. Circulation 2004; 110:3766-72.
66. Manolis AS. The deleterious consequences of right ventricular apical pacing: time to seek alternate site pacing. Pacing Clin Electrophysiol 2006;29:298-315.
67. Gebauer RA, Tomek V, Kubus P, et al. Differential effects of the site of permanent epicardial pacing on left ventricular synchrony and function in the young: implications for lead placement. Europace 2009;11:1654-9.
68. Gebauer RA, Tomek V, Salameh A, et al. Predictors of left ventricular remodelling and failure in right ventricular pacing in the young. Eur Heart J 2009;30:1097-104.
69. Taylor-Albert E, Reichlin M, Toews WH, et al. Delayed dilated cardiomyopathy as a manifestation of neonatal lupus: case reports, autoantibody analysis, and management. Pediatrics 1997; 99:733-5.
70. Moak JP, Barron KS, Hougen TJ, et al. Congenital heart block: development of late-onset cardiomyopathy, a previously underappreciated sequela. J Am Coll Cardiol 2001;37:238-42.
71. Udink ten Cate FE, Breur JM, Cohen MI, et al. Dilated cardiomyopathy in isolated congenital complete atrioventricular block: early and long-term risk in children. J Am Coll Cardiol 2001; 37:1129-34.
72. Moak JP, Hasbani K, Ramwell C, et al. Dilated cardiomyopathy following right ventricular pacing for AV block in young patients: resolution after upgrading to biventricular pacing systems. J Cardiovasc Electrophysiol 2006;17:1068-71.
73. Takabayashi S, Shimpo H, Mitani Y, Komada Y. Pediatric cardiac remodeling after cardiac resynchronization therapy. Pediatr Cardiol 2006;27:485-9.
74. Wilkoff BL, Cook JR, Epstein AE, et al. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA 2002;288:3115-23.
75. Sweeney MO, Hellkamp AS, Ellenbogen KA, et al. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation 2003;107:2932-7.
76. Curtis AB, Adamson PB, Chung E, et al. Biventricular versus right ventricular pacing in patients with AV block (BLOCK HF): clinical study design and rationale. J Cardiovasc Electrophysiol 2007;18:965-71.
77. Spragg DD, Kass DA. Pathobiology of left ventricular dys synchrony and resynchronization. Prog Cardiovasc Dis 2006;49:26-41.
78. McAlister FA, Ezekowitz J, Hooton N, et al. Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review. JAMA 2007;297:2502-14.
79. Ghio S, Freemantle N, Scelsi L, et al. Long-term left ventricular reverse remodelling with cardiac resynchronization therapy: results from the CARE-HF trial. Eur J Heart Fail 2009;11:480-8.
80. St John Sutton M, Ghio S, Plappert T, et al. Cardiac resynchronization induces major structural and functional reverse remodeling in patients with New York Heart Association class I/II heart failure. Circulation 2009;120:1858-65.
81. Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009;361:1329-38.
82. Janousek J, Vojtovic P, Hucin B, et al. Resynchronization pacing is a useful adjunct to the management of acute heart failure after surgery for congenital heart defects. Am J Cardiol 2001;88:145-52.
83. Rodriguez-Cruz E, Karpawich PP, Lieberman RA, Tantengco MV. Biventricular pacing as alternative therapy for dilated cardiomyopathy associated with congenital heart disease. Pacing Clin Electrophysiol 2001;24:235-7.
84. Blom NA, Bax JJ, Ottenkamp J, Schalij MJ. Transvenous biventricular pacing in a child after congenital heart surgery as an alternative therapy for congestive heart failure. J Cardiovasc Electrophysiol 2003;14:1110-2.
85. Zimmerman FJ, Starr JP, Koenig PR, et al. Acute hemodynamic benefit of multisite ventricular pacing after congenital heart surgery. Ann Thorac Surg 2003;75:1775-80.
86. Strieper M, Karpawich P, Frias P, et al. Initial experience with cardiac resynchronization therapy for ventricular dysfunction in young patients with surgically operated congenital heart disease. Am J Cardiol 2004;94:1352-4.
87. Senzaki H, Kyo S, Matsumoto K, et al. Cardiac resynchronization therapy in a patient with single ventricle and intracardiac conduction delay. J Thorac Cardiovasc Surg 2004;127:287-8.
88. van Beek E, Backx A, Singh S. Cardiac resynchronization as ther apy for congestive cardiac failure in children dependent on chronic cardiac pacing. Cardiol Young 2006;16:187-9.
89. Jones BO, Davis AM, Alison J, et al. Cardiac re-synchronization therapy in a child with severe anthracycline-induced congestive heart failure and normal QRS duration. J Heart Lung Transplant 2007;26:1333-5.
90. Sojak V, Mazic U, Cesen M, et al. Cardiac resynchronization therapy for the failing Fontan patient. Ann Thorac Surg 2008;85:2136-8.
91. Dubin AM, Janousek J, Rhee E, et al. Resynchronization therapy in pediatric and congenital heart disease patients: an international multicenter study. J Am Coll Cardiol 2005;46: 2277-83.
92. Janousek J, Gebauer RA, Abdul-Khaliq H, et al. Cardiac resynchronisation therapy in paediatric and congenital heart disease: differential effects in various anatomical and functional substrates. Heart 2009;95:1165-71.
93. Karpawich PP. Technical aspects of pacing in adult and pediatric congenital heart disease. Pacing Clin Electrophysiol 2008;31(Suppl 1):S28-31.
94. Macicek SM, Macias CG, Jefferies JL, et al. Acute heart failure syndromes in the pediatric emergency department. Pediatrics 2009;124:e898-904.
95. Salvador DR, Rey NR, Ramos GC, Punzalan FE. Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Database Syst Rev 2004;CD003178.
96. Subhedar NV, Shaw NJ. Dopamine versus dobutamine for hypotensive preterm infants. Cochrane Database Syst Rev 2000;CD001242.
97. Hoffman TM, Wernovsky G, Atz AM, et al. Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease. Circulation 2003;107:996-1002.
98. Cuffe MS, Califf RM, Adams KF Jr, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002;287:1541-7.
99. Artman M, Graham TP Jr. Guidelines for vasodilator therapy of congestive heart failure in infants and children. Am Heart J 1987;113:994-1005.
100. Publication Committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002;287:1531-40.
101. Abraham WT, Adams KF, Fonarow GC, et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol 2005;46:57-64.
102. Mahle WT, Cuadrado AR, Kirshbom PM, et al. Nesiritide in infants and children with congestive heart failure. Pediatr Crit Care Med 2005;6:543-6.
103. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Shortterm risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 2005;293:1900-5.
104. Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised doubleblind trial. Lancet 2002;360:196-202.
105. Namachivayam P, Crossland DS, Butt WW, Shekerdemian LS. Early experience with levosimendan in children with ventricular dysfunction. Pediatr Crit Care Med 2006;7:445-8.
106. Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007;297:1883-91.
107. Gheorghiade M, Konstam MA, Burnett JC Jr, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 2007;297:1332-43.
108. Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007;297:1319-31.
109. McMurray JJ, Teerlink JR, Cotter G, et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 2007;298:2009-19.
110. Stiller B, Lemmer J, Schubert S, et al. Management of pediatric patients after implantation of the Berlin Heart EXCOR ventricular assist device. ASAIO J 2006;52:497-500.
111. Boehmer JP, Popjes E. Cardiac failure: mechanical support strategies. Crit Care Med 2006;34(9 Suppl):S268-77.
112. Costanzo MR, Guglin ME, Saltzberg MT, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized with acute decompensated heart failure. J Am Coll Cardiol 2007;49: 675-83.
113. O'Sullivan JJ, Roche SL, Crossland DS, et al. Recovery of heart function in children with acute severe heart failure. Transplantation 2008;85:975-9.
114. Amabile N, Fraisse A, Bouvenot J, et al. Outcome of acute fulminant myocarditis in children. Heart 2006;92:1269-73.
115. Price JF, Mott AR, Dickerson HA, et al. Worsening renal function in children hospitalized with decompensated heart failure: evidence for a pediatric cardiorenal syndrome?. Pediatr Crit Care Med 2008;9:279-84.
116. Kirk R, Naftel D, Hoffman TM, et al. Outcome of pediatric patients with dilated cardiomyopathy listed for transplant: a multiinstitutional study. J Heart Lung Transplant 2009;28:1322-8.